One potentially significant change among the drugs.

No direct equivalence of the terzetto marketed agents has been conducted, particularly with greeting to efficacy measures. One potentially significant change among the drugs, however, is vardenafil’s possibility for protraction of the QTc separation, a development associated with ventricular dysrhythmias and sudden cardiac destruction. Although no reports of this question have been published, patients should be carefully screened and monitored. Vardenafil should not be administered to patients with congenital QTc duration or those receiving Teaching IA or III antiarrhythmic agents. Cardiac conduction disorders are also more likely when the PDE5 inhibitor is used concomitantly with CYP 3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin). Vardenafil is also contraindicated for use in patients receiving alpha-adrenergic sensory receptor antagonists, medications commonly administered for the governance of benign prostatic hyperplasia. The same holds true for soft tabs tadalafil, with the instance of doses up to 0.4 mg daily of tamsulosin (Flomax — Boehringer Ingelheim).
This is a part of article One potentially significant change among the drugs. Taken from "Soft Tab Cialis" Information Blog